Fate Therapeutics (NASDAQ:FATE) Earns Neutral Rating from Wedbush
Wedbush reissued their neutral rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report report published on Monday, Marketbeat reports. The brokerage currently has a $7.00 price objective on the biopharmaceutical company’s stock. Wedbush also issued estimates for Fate Therapeutics’ Q1 2024 earnings at ($0.42) EPS, Q2 2024 earnings at ($0.43) […]
More Stories
FDA Investigating Deaths Potentially Linked to COVID-19 Vaccines Across Age Ranges
By Aldgra Fredly The U.S. Food and Drug Administration (FDA) is looking into the potential links between COVID-19 vaccination and...
Who is Bindi Irwin? Her Life, Career, Family & Awards
One of the most loved Australian wildlife conservationists, Bindi Irwin. She is also a television personality, actress, and the CEO...
State Department Has Revoked 85,000 Visas Since January, Official Says
By Jacob Burg The Trump administration has rescinded 85,000 visas across all categories since President Donald Trump’s inauguration in January,...
More Than 100 Cases of Norovirus Reported on Cruise Ship: CDC
By Jack Phillips A norovirus outbreak has sickened more than 100 people on an Aida Cruises ship, according to an...
Student Sues North Carolina School District After Tribute to Charlie Kirk Is Censored
By Tom Ozimek A North Carolina high school student and her parents have sued the Charlotte-Mecklenburg Board of Education, alleging...
Trump Warns ‘Biggest Threat’ to US Would Be Supreme Court Overruling Tariffs
By Jack Phillips President Donald Trump on Tuesday said that national security could be at risk if the Supreme Court...